No Data
No Data
Bronco B, SE H&I, Good Product Plan, etc.
<4503> Astellas Pharma fell sharply by 55 to 1642. Jefferies Securities downgraded its investment rating from "buy" to "hold" and lowered its target stock price from 2100 yen to 1700 yen. Sales forecasts for overactive bladder treatment Mirabegron, hot flush treatment Veoza, and geographic atrophy treatment Izervay have been downwardly revised, and annual revenue estimates for the next five years are expected to decrease by an average of 5%. The EBITDA estimate appears to be about 9% below consensus. <7
Active and newly listed stocks during the morning session.
*Shibaura Mechatronics <6590>: 8780 +590. The rebound in the SOX index caused a strong backlash from the previous day's sharp decline. *Yamashin Filter <6240>: 522 +32 continues to be sought after as a Trump-related stock. *FP Partner <7388>: 3235 +170 maintains a predominant upward trend after the first half earnings report. *Ryohin Keikaku <7453>: 2825 +147.5 has its target stock price raised at Mizuho Securities. *Ezaki Glico <2206>: 4606 +203 has Dalton Investments become a major shareholder.
Hot stocks digest (morning): Fuji Pharma, Bronco B, WOLVES, etc.
Furuya Metal <7826>: up 85 yen to 4505 yen. The company announced a downward revision of its financial estimates the previous day, with operating profit for the fiscal year ending June 24 decreasing 15.5% from the previous year's estimate to 9.7 billion yen from 10.2 billion yen. The delay in the sales recovery of the thin film division and the fine chemical recycling department is believed to be the reason. However, there were strong concerns about lower-than-expected results based on the situation until the third quarter, and the negative reaction was limited. On the other hand, with the implementation of a commemorative dividend of 30 yen, the annual dividend is expected to be 256 yen as previously forecasted.
Bronco B and others continue to rank in, with a prevalent feeling that performance estimates have been fully revised upward.
Bronco B <3091> ranked in (as of 10:32 a.m.). It fell significantly. The company announced its first-half financial results the day before, with operating profit reaching 1.22 billion yen, 2.1 times higher than the same period last year, greatly exceeding the previous financial estimate of 0.94 billion yen. As a result, the full-year forecast has been revised upward from the previous 1.95 billion yen to 2.27 billion yen, an increase of 38.0% compared to the previous period. However, the performance upside from the first quarter profit level has been priced in, and the revision range is expected to be in line with expectations, leading to a sense of exhaustion. Done.
Volume change rate ranking (9:00 am) - Libomic, Yumiru link and other companies are ranked in.
*In volume change rate rankings, you can understand the interest of market participants, such as trending stocks, by comparing the volume for the most recent 5 days with the volume on the day of release. *Volume Change Rate Ranking Top [as of 9:32 on July 19] (Comparison with the most recent 5-day average volume): Stock Code and Name Volume 5-day Average Volume Volume Change Rate Stock Price Change Rate <7446> Tohoku Chemical 200 107185.08 400% 0% <3409> Kita-Nippon Bank
Investment Strategy for July 19th [Today]
[FISCO Featured Stocks] [Material Stocks] En Japan <4849> 2727 yen (7/18) operates job posting websites and provides personnel placement services. On June 21, it announced that it will participate in the sale of its shares due to Time's listing and sell all of its shareholdings in the company. With the determination of the sale price, the expected special profit will be recorded as investment securities gains, and the net profit for the fiscal year ending March 25th is expected to be 9.33 billion yen, 2.2 times the previous year's profit, increasing the previous estimate by about 61%.
No Data